About the Journal
About this Journal: Who We Are, and What We Stand For
Genetics and Clinical Genomics is driven by an altruistic mission: to advance global health through the transformative power of genomics. We share this vision with clinicians, researchers, educators, policymakers, patients, and the public, united in the belief that genetics and genomics can unlock solutions to some of the world's most pressing health challenges.
This mission defines us beyond the format of our content. Whether through research publications, educational initiatives, webinars, podcasts, or digital resources, Genetics and Clinical Genomics strives to remain a beacon for progress in clinical genetics and genomics.
Our priorities are rooted in:
- Advancing the creation and dissemination of genomic research to improve human health.
- Fostering equitable access to genomic knowledge and technologies.
- Promoting interdisciplinary clinical education to empower practitioners and researchers.
- Advocating for patient-centered approaches in genetic care and innovation.
- Addressing social and ethical dimensions of genomics to ensure fairness, inclusivity, and sustainability.
In pursuing these goals, we are committed to transparency, accountability, and genuine collaboration with patients, families, and communities. By amplifying underrepresented voices and prioritizing the needs of those most vulnerable, we seek to ensure the benefits of genomic progress are shared universally.
Genetics and Clinical Genomics is more than a journal; it is a partner, educator, advocate, and innovator. Whether as a trusted academic resource, an inspiring collaborator, or a call to action—we invite you to join us in this shared mission. Together, we can leverage the potential of genomics to create a healthier, more equitable world for all.
The Journal is open and publishes original unpublished articles, review topics, clinical case reports, relevant short communications, letters to the editor, as well as related opinions expressed in editorials. Manuscripts will be accepted for publication only if they have not been previously published.
The journal has started with two publication options, free and open access. The free option allows any author to submit their manuscript at no additional cost. The open access version uses the CCBY 4.0 license, which allows placement of your manuscript in HTML version and free redistribution of the manuscript.
About the Editorial
Infomedic International.
Paitilla Medical Offices, #430
Panama, Rep. of Panama
www.infomedicint.com
First edition: June 2023.
eISSN: 2953-3139 (Spanish)
eISSN: L 3072-9610 (English)
This publication is distributed under the Creative Common licenses.
For more information contact the publisher.
The Journal assumes no responsibility for the consequences of the use of the information contained in its publications. They reflect the exclusive point of view of their authors.
Best Practices
The Journal adheres to the best practices, recommendations and procedures proposed by the Committee on Advertising Ethics (COPE) for the publication of scientific journals.
Authors must take into account the principles of the World Medical Association on human research and the well-known Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration-of-helsinki- principios-éticos-para-la-investigación-medica-en-sujetos-humanos/).
The Journal also endorses the ICMJE recommendations for the conduct, writing, editing and publication of papers in medical journals (http://www.icmje.org/recomendaciones/).
Clinical studies should use CONSORT or TREND guidelines when appropriate. Meta-analysis studies should follow PRISMA guidelines. Diagnostic reports should follow STARD guidelines. Epidemiological studies should consult with the STROBE Initiative. Microarray reports should follow MIAME guidelines and be published in accessible repositories. In biomedical research, authors can evaluate BioShari guidelines.
Human studies
In the case of clinical experiments in humans, the studies must have institutional and ethics committee approval, statements of the implementation of good clinical practices, and document how informed consent was obtained. If requested by the Journal, authors should provide this material. This includes following the principles of the Declaration of Helsinki. In addition, registration of clinical trials with WHO or ICMJE may be requested.
Animal studies
Animal studies must be conducted in accordance with internationally accepted standards. Institutions must obtain approvals from their institutional or equivalent committees (ethics committees). This information should be reported in the manuscript.
Informed Consent
Studies should follow privacy standards and request signed informed consent. The Journal requires the request of consent by the investigators to the subjects of the study, under the WHO/WHO international regulations and compliance with local regulations. Studies containing personally identifiable information will not be accepted.
Declaration of conflict of interest and sources of funding
Authors should also declare any possible conflict of interest in a short paragraph at the end of their manuscript. Our journal is regulated under the guidelines of the International Committee of Medica Journal Editors (ICMJE). This declaration includes owning stock, providing consulting services, organizational memberships, financial partnerships, travel fees, or royalties. A conflict of interest should be identified by any direct or indirect benefit, whether financial or not, derived from the publication and provided by a third party. Likewise, authors should disclose the source of funding for their work or any sponsor that supported the research directly or indirectly.
When the author submits the manuscript, each listed co-author will receive an e-mail with a link to a digital potential conflict of interest form. This form should be filled out by each co-author by clicking on the submit button. The model form was taken from the International Committee of Medical Editors.
Image of the Digital Conflict of Interest form/Image of the Digital Conflict of Interest form
Once the material is received you will be sent an email informing you of this. Your paper will be read by the editors, and if it is accepted for review you will receive a notification. It will be subject to peer review. It will then be forwarded to you with the editors' comments, questions and suggestions. They should return the responses and changes in a separate file, where the changes are shown and marked. When publications are accepted, authors should take into account that this material cannot be published in another journal. The journal reserves the right to require compliance with these rules.
Cost of publication
At the moment, we offer two ways to publish. The Standard License: which is Free-of-Charge, allows anyone to submit their manuscript, and if the manuscript is accepted, it will be published at no cost. This agreement grants the Editorial an exclusive license and rights to publish and distribution. This is specially beneficial for Students, Residents, or groups that are not funded.
The second method is to publish through the Full Open Access (CC-BY) option, which requires a $450.00 USD fee after the manuscript is accepted for publication by the journal. Any work that has been financed must be submitted through the Full Open Access option. This is considered a non-exclusive license agreement between the author(s) and the Editorial.
Distribution, use and license
Through the Standard License, the authors grant exclusive license to the Publisher for the reproduction and distribution of the material submitted through the Standard agreement. The published content may be used for individual and academic use, and not for commercial use or redistribution. For commercial use of the material, or its distribution, redistribution requires written permission from the Publisher.
The use of material presented through this site must not be modified, nor any image extracted, nor any logo removed. Any identification of its primary source must be presented as is in the digital document.
Authors’ rights and open access options
The Journal Licence allows authors to use their articles for their own non-commercial purposes without seeking permission from us – the only condition being that a full reference or link to the original is included.
Version December 2024
